Casdin Capital
Jing He, Research Analyst, joined Casdin Capital in 2021 and focuses on therapeutics. Jing brings 10 years of experience in both investment management and pharmaceutical industry.
Prior to joining Casdin, Jing served as a healthcare portfolio manager and analyst at Gabelli Funds where she covered the biopharmaceutical industry. Her prior experience includes time at Alliance Bernstein and SVB Leerink. She began her career at Regeneron Pharmaceuticals as a scientist in drug research and development where she worked on drugs including Eylea, Dupixent and Praluent.
Jing earned an MBA from Columbia Business School, a Masters in Chemistry from Washington University in St. Louis and a B.S. in Chemistry from Peking University.
Casdin Capital
1 followers
Casdin Capital, LLC (“Casdin”) is a New York-based fundamental research investment firm focused on the life sciences and healthcare industry. The firm manages a long short equity fund and makes investments in early stage to late stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management. Casdin started from a position of curiosity, honesty, and passion to gain a deep and thoughtful understanding of opportunities in the life science ecosystem. They commit to finding the highest quality management teams doing the work to create high growth companies. They use data to continually advance their knowledge and we are long term investors. They believe in collaboration and transparency and operate at the forefront of innovation.